<DOC>
	<DOC>NCT00739960</DOC>
	<brief_summary>The purpose of this study is to determine how safe and effective Abatacept is in treating patients who have progressive pulmonary sarcoidosis.</brief_summary>
	<brief_title>Safety Study of Abatacept to Treat Refractory Sarcoidosis</brief_title>
	<detailed_description />
	<mesh_term>Sarcoidosis</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Primary Diagnosis of sarcoidosis for at least 1 year with lung disease Active disease despite current treatment On a stable dose of sarcoidosis treatment with oral steroids, methotrexate, or hydroxychloroquine, for at least 90 days Primary Previous treatment with Abatacept Currently receiving or received within the last 60 days the following: TNFÎ±inhibitors (infliximab, etanercept, adalimumab) Currently receiving or received within the last 30 days the following: cyclosporine, tacrolimus or leflunomide Previous treatment of IVIg within the last 6 months History of chronic infection that has been active within last 60 days, or herpes zoster within last 6 months, or any infection requiring hospitalization or intravenous medication within last 60 days or oral medication within the last 2 weeks History of congestive heart failure HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>